Efficacy of antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term cardiovascular prognosis in patients with asymptomatic paroxysmal atrial fibrillation: Comparison to patients with symptomatic atrial fibrillation

International Heart Journal

Volumn 51, Issue 2, 2010, Pages 98-104

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Sato, Yoshihiro ^a   Ozawa, Mahito ^a   Kunugida, Fusanori ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic therapy; Atrial fibrillation; Ischemic stroke; Prognosis; Prophylactic efficacy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; APRINDINE; CIBENZOLINE; DISOPYRAMIDE; FLECAINIDE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RECURRENT DISEASE; SINUS RHYTHM; SURVIVAL RATE; SYMPTOM; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 77951481204     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.98     Document Type: Article

References (25)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
3. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99: 3028-35.
4. Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 1996; 17 (Suppl C): 48-51. (Review)
5. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
6. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47-52.
7. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 700-52.
8. Klein AL, Grimm RA, Murray RD, et al. Use of transesopha-geal echocardiography to guide cardioversion in patients with atrial fibrillation. N Eng J Med 2001; 344: 1411-20.
9. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-37A. (Review)
10. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-63.
11. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
12. Komatsu T, Nakamura S, Suzuki O, Horiuchi D, Yomogida K Okumura K. Long-term prognosis of patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004; 68: 729-33.
13. Komatsu T, Tachibana H, Sato Y, et al. Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation. Int Heart J 2009: 50: 465-76.
14. Farina E, Magni E, Ambrosini F, et al. Neuropsychologic deficits in asymptomatic atrial fibrillation. Ada Neurol Scand 1997;96:310-6.
15. Sugishita K, Shiono E, Sugiyama T, Ashida T. Diabetes influences the cardiac symptoms related to atrial fibrillation. Circ J 2003;67:835-8.
16. Wolk R, Kulakkowski P, Karczmarewicz S, et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol 1996; 54:207-11.
17. Atarashi H, Ogawa S, Inoue H, Hamada C; Flecainide Atrial Fibrillation Investigators. Dose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial. Circ J 2007; 71:294-300.
18. Iga K, Izumi C, Nakao A, et al. Problems in pharmacological evaluation of patients with paroxysmal atrial fibrillation: clinical analysis of more than 100 consecutive patients. Inter Med 1998; 37: 1005-8.
19. Allessie MA. Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998; 9: 1378-93. (Review)
20. Komatsu T, Sato Y, Tachibana H, Nakamura M, Horiuchi D, Okumura K. Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy. Circ J 2006; 70: 667-72.
21. Komatsu T, Ozawa M, Tachibana H, et al. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. Int Heart J 2008; 49: 435-47.
22. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
23. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
24. Defaye P, Doumaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol 1998; 21: 250-5.
25. Fukuda Y, Akashi M, Noma S, Mitamura H, Ogawa S: Asymptomatic recurrence of atrial fibrillation: Cardiophone-guided management. Circ J 2003; 67: 310.